RxSalesPros

MedTech

AMPEL BioSolutions | July 07, 2022

AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for tre...

Cell and Gene Therapy, Industrial Impact

Sana Biotechnology | January 30, 2023

Sana Biotechnology, Inc., a firm focused on producing and delivering engineered cells as medicines, recently announced that the FDA has approved the company's Investigational New Drug (IND) application to begin a first-in-human trial of SC291 in patients with different types of B-cell malignancies. SC291 is an allogeneic CAR T cell therapy that targets CD19. It is developed by Sana using its hypoimmune platform. The hypoimmune platform's objective is to overcome the allo...

Cell and Gene Therapy, Medical

QIAGEN | January 11, 2023

QIAGEN recently announced its acquisition of Verogen, a leader in utilizing next-generation sequencing (NGS) technologies to advance the future of human identification (HID) and forensic investigation. QIAGEN, which introduced the first commercial kits to purify DNA from forensic casework samples in the late 1990s, is one of the leaders in the HID/forensics sector. Verogen, a privately-owned company launched in 2017, provides NGS tools and professional services to t...

Medical

PhageNova Bio, Inc. | December 14, 2020

PhageNova Bio, Inc. ("PhageNova") is pleased to declare the distribution of information created through a sponsored research agreement with Rutgers, The State University of New Jersey. The Med (a Cell Press distribution) article, entitled Targeted Phage Display-Based Pulmonary Vaccination in Mice and Non-human Primates, portrays another technique for protected and effective pulmonary delivery of therapeutics, including an aerosol vaccination strategy which is being developed to address...